Abstract
Hypertension is a major risk factor for atherosclerotic cardiovascular disease. Selectins, cell-surface adhesion molecules involved in leukocyte rolling and attachment to the vascular endothelium, play a role in the initiation of atherosclerosis. We investigated whether or not serum levels of soluble adhesion molecules are elevated in patients with essential hypertension (EH) and examined whether antihypertensive therapy lowers such levels. Twenty-one patients who had untreated mild to moderate EH without diabetes mellitus, hyperlipidemia, or obesity were recruited at a clinic for hypertensive patients. Blood pressure was measured, and the serum levels of soluble E-selectin, P-selectin, L-selectin, intercellular adhesion molecule 1 (ICAM-1), and vascular-cell adhesion molecule 1 (VCAM-1) were determined by enzyme-linked immunosorbent assays before and after 12, 24, and 53 weeks of antihypertensive treatment with benidipine, a long-acting calcium channel blocker, given at a dose of 6 mg/day for 53 weeks. As a control, 21 age- and sex-matched patients without hypertension were studied. Serum E- and P-selectin levels were significantly higher in the subjects with EH than in the controls (p<0.01). There were no differences in serum levels of soluble L-selectin, VCAM-1, or ICAM-1 levels between the patients with EH and the controls. Treatment with benidipine decreased the elevated blood pressure over a 53-week study period (mean blood pressure: 119.8±6.5 mmHg at baseline, 101.0±5.9 mmHg at 12 weeks, 98.6±7.3 mmHg at 24 weeks, and 93.9±5.5 mmHg at 53 weeks). Serum levels of soluble E- and P-selectin decreased after the initiation of benidipine treatment and correlated with diastolic blood pressure. Serum levels of soluble L-selectin, VCAM-1, and ICAM-1 did not change significantly during the period of benidipine treatment. Benidipine treatment reduced the content of P-selectin in the platelets from patients with EH, as determined by Western blot analysis. In conclusion, decreased blood pressure may reduce the rate of progression of atherosclerosis by affecting the expression of E- and P-selectin in the endothelium, the platelets, or both. Benidipine may be protective against vascular damage in people with hypertension, not only by lowering blood pressure, but also by inhibiting the expression of selectins.
Similar content being viewed by others
Article PDF
References
Price DT, Loscalzo J : Cellular adhesion molecules and atherogenesis. Am J Med 1999; 107: 85–97.
Pigott R, Dillon LP, Hemingway IH, et al: Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. Biochem Biophys Res Commun 1992; 187: 584–589.
Blann AD, Tse W, Maxwell SJ, et al: Increased levels of the soluble adhesion molecule E-selectin in essential hypertension. J Hypertens 1994; 12: 925–928.
Verhaar MC, Beutler JJ, Gaillard CA, et al: Progressive vascular damage in hypertension is associated with increased levels of circulating P-selectin. J Hypertens 1998; 16: 45–50.
Ogihara T, Kuramoto K : Effect of long-term treatment with antihypertensive drugs on quality of life of elderly patients with hypertension: a double-blind comparative study between a calcium antagonist and a diuretic. NICS-EH Study Group. National Intervention Cooperative Study in Elderly Hypertensives. Hypertens Res 2000; 23: 33–37.
Ishimitsu T, Kobayashi T, Honda T, et al: Protective effects of an angiotensin II receptor blocker and a long-acting calcium channel blocker against cardiovascular organ injuries in hypertensive patients. Hypertens Res 2005; 28: 351–359.
Iino Y, Hayashi M, Kawamura T, et al: Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension—a report of the Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) Study. Hypertens Res 2004; 27: 21–30.
Simon A, Gariepy J, Moyse D, Levenson J : Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes. Circulation 2001; 103: 2949–2954.
Pitt B, Byington RP, Furber CD, et al, PREVENT Investigators : Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000; 102: 1503–1510.
McDonagh RF, Rauzzino MJ : Stimulated leukocyte adhesion in coronary microcirculation is reduced by a calcium antagonist. Am J Physiol 1993; 34: H476–H483.
Alexander JJ, Miguel R, Piotrowski JJ : The effect of nifedipine on lipid and monocyte infiltration of the subendothelial space. J Vasc Surg 1993; 17: 841–847.
Johnson GJ, Leis LA, Francis GS : Disparate effects of the calcium-channel blockers, nifedipine and verapamil, on alpha 2-adrenergic receptors and thromboxane A2-induced aggregation of human platelets. Circulation 1986; 73: 847–854.
Kobayashi N, Nakano S, Mori Y, Kobayashi T, Tsubokou Y, Matsuoka H : Benidipine inhibits expression of ET-1 and TGF-beta1 in Dahl salt-sensitive hypertensive rats. Hypertens Res 2001; 24: 241–250.
Otsuka K : Efficacy and safety of 6 mg benidipine, long-acting calcium channel blocker, in patients with essential hypertension. Clin Rep 2000; 77: 1788–1796.
Fukuoka Y, Nagashima R, Oonishi Y, et al: Blood pressure control by benidipine, long-acting calcium channel blocker, in hypertensive patients. J N Remed Clin 2001; 50: 633–639.
Morikawa T, Okumura M, Konishi Y, Okada N, Imanishi M : Effects of benidipine on glomerular hemodynamics and proteinuria in patients with nondiabetic nephropathy. Hypertens Res 2002; 25: 571–576.
Takahashi H, Munakata M, Komiyama Y, et al: Effects of benidipine on the function of platelets and endothelial cells in patients with essential hypertension. J Blood Pressure 1998; 5: 1199–1204.
Malmqvist K, Wallen HN, Held C, Kahan T : Soluble cell adhesion molecules in hypertensive concentric left ventricular hypertrophy. J Hypertens 2002; 20: 1563–1569.
Nomura S, Kanazawa S, Fukuhara S : Effects of efonidipine on platelet and monocyte activation markers in hypertensive patients with and without type 2 diabetes mellitus. J Hum Hypertens 2002; 16: 539–547.
Miller MA, Kerry SM, Cook DG, Cappuccio FP : Cellular adhesion molecules and blood pressure: interaction with sex in a multi-ethnic population. J Hypertens 2004; 22: 705–711.
Ferri C, Bellini C, Desideri G, et al: A clustering of endothelial markers of vascular damage in human salt-sensitive hypertension: influence of dietary sodium load and depletion. Hypertension 1998; 32: 862–868.
DeSouza CA, Dengel DR, Macko RF, Cox K, Seals DR : Elevated levels of circulating cell adhesion molecules in uncomplicated essential hypertension. Am J Hypertens 1997; 10: 1335–1341.
Li-Saw-Hee FL, Beevers DG, Lip GY : Effect of antihypertensive therapy using enalapril or losartan on haemostatic markers in essential hypertension: a pilot prospective randomised double-blind parallel group trial. Int J Cardiol 2001; 78: 241–246.
Hlubocka Z, Umnerova V, Heller S, et al: Circulating intercellular cell adhesion molecule-1, endothelin-1 and von Willebrand factor-markers of endothelial dysfunction in uncomplicated essential hypertension: the effect of treatment with ACE inhibitors. J Hum Hypertens 2002; 16: 557–562.
Ferri C, Desideri G, Valenti M, et al: Early upregulation of endothelial adhesion molecules in obese hypertensive men. Hypertension 1999; 34: 569–573.
Bagg W, Ferri C, Desideri G, Gamble G, Ockelford P, Braatvedt G D : The influences of obesity and glycemic control on endothelial activation in patients with type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 5491–5497.
Kent JW Jr, Comuzzie AG, Mahaney MC, et al: Intercellular adhesion molecule-1 concentration is genetically correlated with insulin resistance, obesity, and HDL concentration in Mexican Americans. Diabetes 2004; 53: 2691–2695.
Ferri C, Desideri G, Baldoncini R, et al: Early activation of vascular endothelium in nonobese, nondiabetic essential hypertensive patients with multiple metabolic abnormalities. Diabetes 1998; 47: 660–667.
Bluher M, Unger R, Rassoul F, Richter V, Paschke R : Relation between glycaemic control, hyperinsulinaemia and plasma concentrations of soluble adhesion molecules in patients with impaired glucose tolerance or type II diabetes. Diabetologia 2002; 45: 210–216.
Jilma B, Li-Saw-Hee FL, Wager OF, Beevers DG, Lip GYH : Effects of enalapril and losartan on circulating adhesion molecules and monocyte chemotactic protein-1. Clin Sci 2002; 103: 131–136.
Gasic S, Wagner DF, Fasching P, et al: Fosinopril decreases levels of soluble vascular cell adhesion molecule-1 in borderline hypertensive type II diabetic patients with microalbuminuria. Am J Hypertens 1999; 12: 217–222.
Nomura S, Shouzu A, Omoto S, Nishikawa M, et al: Effect of valsartan on monocyte/endothelial cell activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitus. Thromb Res 2005 ( on line publication, in press).
Morisaki N, Otabe M, Saito S : Effects of benidipine on the expression of adhesion molecules on endothelial cells. Ther Res 1999; 20: 2715–2718.
European Society of Hypertension-European Society of Cardiology Guidelines Committee : 2003 European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–1053.
National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee : The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560–2572.
World Health Organization, International Society of Hypertension Writing Group : 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983–1992.
Japan Society of Hypertension Guidelines Committee : Japan Society of Hypertension Guidelines for the Management of Hypertension 2004. Tokyo, Life Science Press, 2004, pp 11–19.
Silacci P, Desgeorges A, Mazzolai L, Chambaz C, Hayoz D : Flow pulsatility is a critical determinant of oxidative stress in endothelial cells. Hypertension 2001; 38: 1162–1166.
Howard AB, Alexander RW, Nerem RM, Griendling KK, Taylor WR : Cyclic strain induces an oxidative stress in endothelial cells. Am J Physiol 1997; 272: C421–C427.
Gosgnach W, Messika-Zeitoun D, Gonzalez W, Philipe M, Michel JB : Shear stress induces iNOS expression in cultured smooth muscle cells: role of oxidative stress. Am J Physiol Cell Physiol 2000; 279: C1880–C1888.
Zalba G, San Jose G, Moreno MU, et al: Oxidative stress in arterial hypertension: role of NAD(P)H oxidase. Hypertension 2001; 38: 1395–1399.
Gille J, Paxton LL, Lawley TJ, Caughman SW, Swerlick RA : Retinoic acid inhibits the regulated expression of vascular cell adhesion molecule-1 by cultured dermal microvascular endothelial cells. J Clin Invest 1997; 99: 492–500.
Yamakado M : Clinical study on antiatherogenic properties of benidipine hydrochloride in patients with essential hypertension. Ther Res 1994; 15: 2733–2738.
Yasunari K, Maeda K, Nakamura M, Watanabe T, Yoshikawa J : Benidipine, a long-acting calcium channel blocker, inhibits oxidative stress in polymorphonuclear cells in patients with essential hypertension. Hypertens Res 2005; 28: 107–112.
Sugawara H, Tobise K, Kikuchi K : Antioxidant effects of calcium antagonists on rat myocardial membrane lipid peroxidation. Hypertens Res 1996; 19: 223–228.
Umemoto S, Tanaka M, Kawahara S, et al: Calcium antagonist reduces oxidative stress by upregulating Cu/Zn superoxide dismutase in stroke-prone spontaneously hypertensive rats. Hypertens Res 2004; 27: 877–885.
Matsubara M, Hasegawa K : Benidipine, a dihydropyridine-calcium channel blocker, prevents lysophosphatidylcholine-induced injury and reactive oxygen species production in human aortic endothelial cells. Atherosclerosis 2005; 178: 57–66.
Fukuo K, Yang J, Suzuki T, et al: Nifedipine upregulates manganese superoxide dismutase expression in vascular smooth muscle cells via endothelial cell-dependent pathways. Hypertens Res 2003; 26: 503–508.
Cominacini L, Garbin U, Pasini AF, et al: Antioxidants inhibit the expression of intercellular cell adhesion molecule-1 and vascular cell adhesion molecule-1 induced by oxidized LDL on human umbilical vein endothelial cells. Free Radic Biol Med 1997; 22: 117–127.
Marui N, Offermann MK, Swerlick R, et al: Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest 1993; 92: 1866–1874.
Takase H, Sugiyama M, Nakazawa A, Sato K, Ueda R, Dohi Y : Long-term effect of antihypertensive therapy with calcium antagonist or angiotensin converting enzyme inhibitor on serum nitrite/nitrate levels in human essential hypertension. Arzneimittelforschung 2000; 50: 530–534.
Yamashita T, Kawashima S, Ozaki M, et al: A calcium channel blocker, benidipine, inhibits intimal thickening in the carotid artery of mice by increasing nitric oxide production. J Hypertens 2001; 19: 451–458.
Kobayashi N, Kobayashi K, Hara K, et al: Benidipine stimulates nitric oxide synthase and improves coronary circulation in hypertensive rats. Am J Hypertens 1999; 12: 483–491.
Whiss PA, Andersson RG, Srinivas U : Modulation of P-selectin expression on isolated human platelets by an NO donor assessed by a novel ELISA application. J Immunol Methods 1997; 200: 135–143.
Lip GY, Blann AD, Zarifis J, Beevers M, Lip PL, Beevers DG : Soluble adhesion molecule P-selectin and endothelial dysfunction in essential hypertension: implications for atherogenesis? A preliminary report. J Hypertens 1995; 13: 1674–1678.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sanada, H., Midorikawa, S., Yatabe, J. et al. Elevation of Serum Soluble E-and P-Selectin in Patients with Hypertension Is Reversed by Benidipine, a Long-Acting Calcium Channel Blocker. Hypertens Res 28, 871–878 (2005). https://doi.org/10.1291/hypres.28.871
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.28.871
Keywords
This article is cited by
-
Irregularities of Coagulation in Hypertension
Current Hypertension Reports (2023)
-
Potential Protective Role of Blood Pressure-Lowering Drugs on the Balance between Hemostasis and Fibrinolysis in Hypertensive Patients at Rest and During Exercise
American Journal of Cardiovascular Drugs (2019)
-
Cancer intelligence acquired (CIA): tumor glycosylation and sialylation codes dismantling antitumor defense
Cellular and Molecular Life Sciences (2015)
-
Circulating levels of cell adhesion molecules in hypertension
Indian Journal of Clinical Biochemistry (2009)